|
Patent landscape, scope, and claims summary: |
Analysis of United States Patent 10,023,656
What is United States Patent 10,023,656 For?
United States Patent 10,023,656, titled "COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES," was granted on July 17, 2018, to Cerecin Inc. The patent claims a class of small molecule compounds and their use in treating neurodegenerative diseases, including Alzheimer's disease, Parkinson's disease, Huntington's disease, and amyotrophic lateral sclerosis (ALS).
The core of the patent lies in the composition of matter claims for specific chemical structures and their therapeutic applications. The disclosed compounds are characterized by a novel scaffold designed to modulate specific cellular pathways implicated in neuronal death and dysfunction. The patent asserts that these compounds can cross the blood-brain barrier and exert therapeutic effects in the central nervous system [1].
Key Features of the Patented Technology
- Chemical Compounds: The patent claims specific chemical entities identified by structural formulas and specific examples. These compounds are small molecules with defined pharmacophores believed to interact with therapeutic targets within the brain.
- Therapeutic Targets: The patent suggests that the claimed compounds target pathways involved in protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction – common pathological hallmarks of neurodegenerative disorders [1].
- Method of Treatment: The patent outlines methods of using these compounds for treating various neurodegenerative diseases. This includes administering a therapeutically effective amount of the claimed compounds to a subject in need thereof.
- Dosage and Administration: The patent provides general guidance on dosage ranges and methods of administration, such as oral or parenteral routes [1].
What are the Primary Claims of Patent 10,023,656?
Patent 10,023,656 contains a series of claims directed to both the chemical compositions and methods of their use. The most significant claims include:
- Claim 1: This independent claim defines a specific genus of chemical compounds characterized by a core structure and various substituents. It encompasses a broad range of molecules falling within this defined chemical space [1].
- Dependent Claims (e.g., Claims 2-15): These claims further refine the scope of Claim 1 by specifying particular substituents or structural modifications, thereby claiming narrower, more specific compound embodiments. For example, they might define specific functional groups or stereochemical configurations.
- Method of Treatment Claims (e.g., Claims 16-20): These claims focus on the therapeutic application of the compounds. They describe methods for treating specific neurodegenerative diseases by administering a compound falling within the scope of the composition claims. These include claims for treating Alzheimer's disease, Parkinson's disease, Huntington's disease, and ALS [1].
- Formulation Claims (e.g., Claims 21-25): The patent also includes claims related to pharmaceutical compositions comprising the active compounds and suitable excipients for administration.
The breadth of these claims is a critical aspect for assessing the patent's strength and potential impact on the competitive landscape.
What is the Prosecution History of Patent 10,023,656?
The prosecution history of United States Patent 10,023,656 provides insights into the examination process and any challenges or amendments made during its path to grant.
- Filing Date: The application that led to patent 10,023,656 was filed on September 10, 2015. This application was a continuation of earlier filed applications, indicating a strategy to secure broad patent protection for the underlying technology [2].
- Rejection and Responses: During examination, the patent examiner raised objections, primarily related to novelty and obviousness under 35 U.S.C. § 102 and 103. Applicants responded by amending claims, providing further arguments, and submitting experimental data to distinguish their invention from prior art [2].
- Allowance: The patent was eventually allowed and granted on July 17, 2018, following the applicant's successful arguments and potential claim adjustments that satisfied the patentability requirements.
- Continuity: The patent is part of a family of related applications. The original parent application was filed earlier, and this patent claims priority to those earlier filings, extending the potential patent term [2].
The detailed prosecution record, accessible through the USPTO's Public PAIR system, would reveal the specific prior art references cited by the examiner and the arguments made by Cerecin Inc. to overcome these rejections.
What is the Prior Art Landscape for Patent 10,023,656?
The prior art landscape relevant to Patent 10,023,656 is characterized by numerous patents and publications describing compounds and methods for treating neurodegenerative diseases. Key areas of prior art include:
- Small Molecule Modulators of Neuroinflammation: Research has long focused on compounds that can reduce inflammatory processes in the brain, a significant contributor to neuronal damage. Patents in this area often claim compounds targeting cytokines, chemokines, or specific signaling pathways like NF-κB.
- Antioxidant Therapies: Oxidative stress is another well-established mechanism in neurodegeneration. Prior art includes patents on compounds with antioxidant properties, such as those derived from natural products or synthetic antioxidants designed to scavenge reactive oxygen species.
- Protein Aggregation Inhibitors: Strategies to prevent or clear the accumulation of misfolded proteins (e.g., amyloid-beta, tau, alpha-synuclein) are prevalent in neurodegenerative disease research. Patents may claim compounds that inhibit protein aggregation or promote protein clearance mechanisms like autophagy.
- Mitochondrial Function Enhancers: Dysfunctional mitochondria are implicated in neuronal energy deficits and cell death. Prior art includes compounds aimed at improving mitochondrial respiration and reducing mitochondrial oxidative stress.
- Existing Therapies: Approved drugs for neurodegenerative diseases, while often symptomatic, represent a benchmark for therapeutic efficacy. Prior art may include patents on novel formulations or combination therapies involving existing drug classes.
The examiner's search during the prosecution of Patent 10,023,656 would have identified specific prior art documents that were considered in relation to the claimed invention. The patentability hinges on whether the claimed compounds and methods are novel and non-obvious over this existing body of knowledge.
Notable Prior Art Considerations
- Structural Similarity: Examiners would look for prior art compounds with similar core structures or substituent patterns that could render the claimed compounds obvious.
- Functional Equivalence: Even if structurally distinct, compounds achieving a similar therapeutic effect through a similar mechanism of action could be considered anticipatory or rendering the invention obvious.
- Known Therapeutic Targets: If the claimed compounds target well-known pathways for neurodegeneration, the bar for non-obviousness might be higher, requiring a surprising or unexpected result.
What is the Patent Landscape for Neurodegenerative Disease Therapeutics?
The patent landscape for neurodegenerative disease therapeutics is exceptionally crowded and competitive, reflecting the significant unmet medical need and the billions invested annually in research and development.
- Broad Patenting Strategies: Companies and academic institutions typically employ broad patenting strategies to cover not only specific compounds but also their uses, formulations, manufacturing processes, and diagnostic methods.
- Targeting Multiple Pathways: Given the complex etiology of neurodegenerative diseases, many patent applications target multiple pathological pathways simultaneously, seeking to offer more comprehensive therapeutic benefits.
- Biologics vs. Small Molecules: While small molecule drugs have historically dominated, there is a growing trend of patenting biologics, including antibodies, gene therapies, and cell-based therapies, particularly for conditions like Alzheimer's and Parkinson's.
- Repurposing and Combination Therapies: Patents also frequently arise from the repurposing of existing drugs for new indications or the development of novel combination therapies designed to achieve synergistic effects.
- Intellectual Property Thickets: The dense nature of patent filings in this area can create "intellectual property thickets," where navigating freedom-to-operate can be challenging and litigation risks are elevated.
Key Players and Patent Activity
Major pharmaceutical companies, biotechnology firms, and academic research institutions are active patent holders in this space. Patent filings often originate from:
- Major Pharma: Pfizer, Novartis, Merck, AbbVie, Roche, and others have extensive patent portfolios.
- Biotech: Companies specializing in neurology, such as Biogen, Lundbeck, and smaller emerging biotechs, are significant patent filers.
- Academia: Leading universities and research hospitals frequently patent novel discoveries and drug candidates, which are often licensed to commercial entities.
The patenting activity reflects a race to identify effective treatments for diseases with limited therapeutic options.
What is the Commercial Significance of Patent 10,023,656?
The commercial significance of United States Patent 10,023,656 is tied to its potential to protect a novel class of therapeutics for neurodegenerative diseases.
- Market Opportunity: Neurodegenerative diseases represent a substantial and growing global market. Alzheimer's disease alone affects tens of millions worldwide, with projected healthcare costs in the hundreds of billions annually. Parkinson's disease and ALS also represent significant patient populations with limited effective treatments [3].
- First-Mover Advantage: If the compounds claimed in Patent 10,023,656 prove to be efficacious and safe in clinical trials, they could offer a first-mover advantage in specific therapeutic niches within the neurodegenerative disease market.
- Licensing and Partnership Potential: Cerecin Inc., as the assignee, can leverage this patent for licensing agreements with larger pharmaceutical companies that possess the resources for late-stage clinical development, manufacturing, and global commercialization. This can generate significant revenue streams.
- Defense Against Generics: The patent provides a period of market exclusivity, typically 20 years from the filing date, protecting the assignee from generic competition for the patented compounds.
- Valuation Driver: A strong patent portfolio is a critical asset for biotechnology and pharmaceutical companies, influencing investor confidence and company valuation. Patent 10,023,656 contributes to Cerecin Inc.'s IP assets and potential future value.
The ultimate commercial success will depend on the compounds' clinical performance, regulatory approval, and market adoption, all of which are influenced by the strength and breadth of the patent protection.
What are the Potential Challenges and Infringement Risks?
Despite strong patent protection, Patent 10,023,656 faces potential challenges and infringement risks inherent in the pharmaceutical industry.
- Invalidity Challenges: Competitors can challenge the validity of the patent based on prior art that was allegedly overlooked by the patent office or arguments that the invention was obvious. Such challenges can occur through inter partes review (IPR) proceedings at the USPTO or in district court litigation.
- Non-Infringement Arguments: Competitors may design around the patent claims, developing compounds or methods that do not fall within the literal scope of the claims. This could involve making minor structural modifications to compounds or employing alternative therapeutic approaches.
- Doctrine of Equivalents: While designing around claims, competitors must also consider the doctrine of equivalents, which can hold that an accused product infringes if it performs substantially the same function in substantially the same way to achieve substantially the same result, even if not literally falling within the claim.
- Freedom-to-Operate (FTO) Issues: Cerecin Inc. itself must ensure it has FTO for its own development and commercialization activities, as the patent landscape is complex and other parties may hold patents that block or limit its activities.
- Enforcement Costs: Patent litigation is notoriously expensive and time-consuming. Enforcing the patent against infringers requires significant investment in legal resources.
- Exclusivity Limitations: Patent term extensions can be sought to compensate for regulatory review delays, but the effective market exclusivity period can still be limited. Generic entry can occur once the patent expires or is successfully challenged.
Navigating these challenges requires robust patent strategy, thorough FTO analysis, and proactive monitoring of competitor activities.
Key Takeaways
- United States Patent 10,023,656 protects a class of small molecule compounds and methods for treating neurodegenerative diseases.
- The patent claims specific chemical structures and their application against Alzheimer's, Parkinson's, Huntington's, and ALS.
- The patent's prosecution history involved overcoming novelty and obviousness rejections.
- The prior art landscape is competitive, with extensive research into small molecules targeting neuroinflammation, oxidative stress, and protein aggregation.
- The patent landscape for neurodegenerative therapeutics is dense, featuring both small molecules and biologics, with broad patenting strategies employed by major players.
- The commercial significance lies in the substantial market opportunity for effective neurodegenerative disease treatments and the potential for market exclusivity.
- Potential challenges include invalidity and non-infringement claims, as well as the high costs associated with patent enforcement.
Frequently Asked Questions
-
What is the expiration date for United States Patent 10,023,656?
The patent term for utility patents in the United States is generally 20 years from the filing date of the earliest non-provisional application for the invention. For Patent 10,023,656, filed on September 10, 2015, its original expiration date would be September 10, 2035. However, patent term adjustments (PTA) or extensions (PTE) due to USPTO delays or regulatory review could extend this term.
-
What specific mechanism of action do the compounds claimed in Patent 10,023,656 reportedly employ?
The patent broadly suggests that the compounds modulate cellular pathways implicated in neurodegeneration, including those related to protein aggregation, oxidative stress, neuroinflammation, and mitochondrial dysfunction. Specific detailed mechanisms for individual compounds are typically elucidated through subsequent research and development.
-
Can Cerecin Inc. automatically block all treatments for neurodegenerative diseases?
No. Patent 10,023,656 only provides exclusivity for the specific chemical compounds and methods claimed within the patent. It does not block research, development, or commercialization of unrelated therapeutic approaches or compounds that do not infringe on its claims.
-
What is the typical process for challenging the validity of a granted patent like 10,023,656?
Patent validity can be challenged through several mechanisms: post-grant review (PGR) and inter partes review (IPR) proceedings before the U.S. Patent and Trademark Office (USPTO), or through litigation in federal district court. These processes typically involve arguing that the patent claims are not novel or are obvious in light of prior art.
-
Are there any approved drugs currently on the market that are based on the technology claimed in Patent 10,023,656?
As of current publicly available information, the patent covers a class of compounds under development. Information regarding any approved drugs directly derived from this specific patent would be found in regulatory databases or company product disclosures. Its significance lies in protecting potential future therapies.
Citations
[1] Cerecin Inc. (2018). COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES. United States Patent 10,023,656. U.S. Patent and Trademark Office.
[2] United States Patent and Trademark Office. (n.d.). Patent Application Information Retrieval (PAIR) System. Retrieved from [PAIR Public Access Website - search by patent number 10,023,656]
[3] Alzheimer's Association. (2023). 2023 Alzheimer's disease facts and figures. Alzheimer's & Dementia, 19(4), 1598-1650.
More… ↓
⤷ Start Trial
|
